Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study

被引：0
|
作者：
Kaseb, Ahmed Omar
Cabrera, Roniel
Iyer, Renuka
Parikh, Neehar
Kalman, Richard
Ozgurdal, Kirhan
Khan, Javeed
Babajanyan, Svetlana
Finn, Richard S.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Florida, Gainesville, FL USA
[3] Roswell Pk Canc Inst, Buffalo, NY USA
[4] Univ Michigan Med, Ann Arbor, MI USA
[5] Einstein Healthcare Network, Philadelphia, PA USA
[6] Bayer, Basel, Switzerland
[7] Bayer PLC, Reading, Berks, England
[8] Bayer Healthcare, Whippany, NJ USA
[9] UCLA Med Ctr, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16114
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [42] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [43] Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice
    Shimose, Shigeo
    Saeki, Issei
    Tomonari, Tetsu
    Ito, Takanori
    Tani, Joji
    Takeuchi, Yasuto
    Yoshioka, Naoki
    Naito, Takehito
    Takeuchi, Mamiko
    Kakizaki, Satoru
    Hatanaka, Takeshi
    Sasaki, Kyo
    Yasunaka, Tetsuya
    Sakata, Masahiro
    Iwamoto, Hideki
    Itano, Satoshi
    Shirono, Tomotake
    Tanabe, Norikazu
    Yamamoto, Takafumi
    Naganuma, Atsushi
    Nishina, Soji
    Otsuka, Motoyuki
    Kawashima, Hiroki
    Takayama, Tetsuji
    Takami, Taro
    Kawaguchi, Takumi
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [44] ANALYSIS OF FACTORS RELATED TO THE TOLERABILITY OF LENVATINIB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CONDITIONS: A MULTICENTER STUDY
    Taniki, Nobuhito
    Nakamoto, Nobuhiro
    Chu, Po-Sung
    Shiba, Shunsuke
    Tahara, Toshiyuki
    Komatsu, Hirokazu
    Okamura, Yukishige
    Ojiro, Keisuke
    Kikuchi, Masahiro
    Aoki, Yu
    Yamaguchi, Akihiro
    Usui, Shingo
    Kanai, Takanori
    HEPATOLOGY, 2020, 72 : 689A - 689A
  • [45] Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices.
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abigail
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
    O'Connor, J. M.
    Ducreux, M.
    Petersen, L. N.
    Oehler, L.
    Bergamo, F.
    Metges, J-P.
    de Groot, J. W.
    Wang, J-Y.
    Garcia Paredes, B.
    Dochy, E.
    Fiala-Buskies, S.
    Cervantes, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study.
    Xue, Feng
    Zhai, Jian
    Liu, Jianwei
    Fu, Zhigang
    Sun, Yanfu
    Ge, Ruiliang
    Bai, Shilei
    Li, Xiaowei
    Wang, Kui
    Qu, Zengqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16125 - E16125
  • [48] Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
    Zhang, Weihong
    Zhu, Bowen
    Tang, Yiyang
    Xue, Miao
    Wu, Yanqin
    Zhao, Yue
    Fan, Wenzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
    Hayakawa, Yuka
    Tsuchiya, Kaoru
    Kurosaki, Masayuki
    Yasui, Yutaka
    Kaneko, Shun
    Tanaka, Yuki
    Ishido, Shun
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Nobusawa, Tsubasa
    Matsumoto, Hiroaki
    Kakegawa, Tatsuya
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Nakanishi, Hiroyuki
    Itakura, Jun
    Takahashi, Yuka
    Asahina, Yasuhiro
    Okamoto, Ryuichi
    Izumi, Namiki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 392 - 402
  • [50] Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
    Ando, Yuwa
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Johira, Yusuke
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Kosaka, Yumi
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Okamoto, Wataru
    Takahashi, Shoichi
    Imamura, Michio
    Chayama, Kazuaki
    Aikata, Hiroshi
    CANCERS, 2021, 13 (16)
12345